Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul-Aug;77(4):499-503.
doi: 10.1590/S1808-86942011000400014.

Betahistine in the treatment of tinnitus in patients with vestibular disorders

[Article in English, Portuguese]
Maurício Malavasi Ganança  1 , Heloisa Helena Caovilla  2 , Juliana Maria Gazzola  3 , Cristina Freitas Ganança  4 , Fernando Freitas Ganança  5
Affiliations

Betahistine in the treatment of tinnitus in patients with vestibular disorders

[Article in English, Portuguese]
Maurício Malavasi Ganança et al. Braz J Otorhinolaryngol. 2011 Jul-Aug.

Abstract

Betahistine is a medicine used to treat vestibular disorders that has also been used to treat tinnitus.

Aim: To assess the effects of betahistine on tinnitus in patients with vestibular disorders.

Material and method: Retrospective data were collected from patient records for individuals presenting with vestibular dysfunction and tinnitus. Patients included had received betahistine 48 mg/day and clinical outcomes were compared with a control group comprising individuals who were unable to receive betahistine due to gastritis, ulcers, pregnancy, asthma or hypersensitivity to the drug. Patients underwent control of any aggravating factors and also standard vestibular exercises as a basis for treatment. The intensity, frequency and duration of tinnitus were assessed on the first day of dosing and after 120 days of treatment. Clinical improvement was defined as a total or partial reduction of tinnitus after treatment.

Results: Clinical improvement was observed in 80/262 (30. 5%) of patients treated with betahistine and 43/252 (17. 1%) of control patients. Betahistine significantly (p<0. 0001) improved tinnitus in treated individuals.

Conclusions: The daily dosage of 48 mg of betahistine during 120 consecutive days is useful to reduce or eliminate tinnitus in patients with vestibular disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparing tinnitus clinical improvement among patients from the study and the control groups.
Figure 2
Figure 2
Comparing tinnitus clinical improvement between a random sample from the study and the control groups.
See this image and copyright information in PMC

References

    1. Henry JA, Dennis KC, Schechter MA. General review of tinnitus: prevalence, mechanisms, effects, and management. J Speech Lang Hear Res. 2005;48:1204–1205. - PubMed
    1. Nondahl DM, Cruickshanks KJ, Dalton DS, Klein BE, Klein R, Schubert CR, et al. The impact of tinnitus on quality of life in older adults. J Am Acad Audiol. 2007;18:257–266. - PubMed
    1. Pinto PCL, Sanchez TG, Tomita S. Avaliação da relação entre severidade do zumbido e perda auditiva, sexo e idade do paciente. Braz J Otorhinolaryngol. 2010;76(1):18–24. - PMC - PubMed
    1. Fornaro M, Martino M. Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management. Neuropsychiatr Dis Treat. 2010;6:209–218. - PMC - PubMed
    1. Axelsson A. In: Reich GF, Vernon JA, editors. 12-15. American Tinnitus Association; Portland, Oregon: 1995. Tinnitus epidemiology. pp. 249–253. (Fifth international tinnitus seminar; 1995; Portland, Oregon. Proceedings.).